AnaptysBio (ANAB) vs Nurix Therapeutics (NRIX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
AnaptysBio (ANAB) has outperformed Nurix Therapeutics (NRIX) over the past year, gaining 76.6% versus a loss of 23.3%. Over five years, ANAB leads with a +124.8% price change compared with -57.3% for NRIX. Nurix Therapeutics is the larger company by market cap ($1.40 billion vs $1.39 billion), about 1.0 times the size, while AnaptysBio is growing revenue faster (+157.0% vs +54.0%).
On valuation, Nurix Therapeutics trades at a lower trailing P/E (5.3x vs 7.2x for AnaptysBio). AnaptysBio converts more of its revenue into profit, with a net margin of -5.6% versus -314.9%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANAB | NRIX |
|---|---|---|
| Share price | $46.63 | $12.85 |
| Market cap | $1.39B | $1.40B |
| 1-day change | -1.62% | -5.55% |
| YTD return | +44.28% | -32.26% |
| 1-year return | +76.58% | -23.33% |
| 5-year return | +124.76% | -57.25% |
| P/E ratio (TTM) | 7.15 | 5.29 |
| Forward P/E | 8.66 | — |
| EPS (TTM) | $6.52 | $2.43 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $234.60M | $83.98M |
| Revenue growth (YoY) | +157.01% | +53.95% |
| Net income (latest FY) | $-13.23M | $-264.46M |
| Operating margin | 96.72% | -340.16% |
| Net margin | -5.64% | -314.90% |
| 52-week high | $72.36 | $28.23 |
| 52-week low | $26.01 | $12.83 |
| Distance from 52-week high | -35.56% | -54.50% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +87.11% | +160.80% |
| Average volume | 496.92K | 2.47M |
| Shares outstanding | 29.73M | 109.25M |
| Employees | — | 317 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANAB has outperformed NRIX by 99.9 percentage points over the past year.
- AnaptysBio trades at a higher earnings multiple (7.2x vs 5.3x trailing P/E).
- AnaptysBio is more profitable, keeping -5.6 cents of every revenue dollar as net income versus -314.9 cents for Nurix Therapeutics.
- AnaptysBio grew revenue faster in its latest fiscal year (+157.01% vs +53.95%).
About AnaptysBio
ANAB stock →AnaptysBio, Inc. discovers and out-licenses therapeutic bodies in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations
About Nurix Therapeutics
NRIX stock →Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, which is in Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor that is in Phase 1a/1b clinical trials to treat immuno-oncology indications.
Health Care · Biotechnology: Pharmaceutical Preparations · 317 employees
ANAB vs NRIX FAQ
Which is bigger, AnaptysBio or Nurix Therapeutics?
Nurix Therapeutics (NRIX) is larger, with a market capitalization of $1.40B compared with $1.39B for AnaptysBio (ANAB).
Which stock has performed better over the past year, ANAB or NRIX?
ANAB returned +76.58% over the past 12 months, compared with -23.33% for NRIX (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ANAB or NRIX?
NRIX has the lower trailing P/E at 5.3, versus 7.2 for ANAB. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are AnaptysBio and Nurix Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.